9,220,770 OCR.pdf (1.72 MB)
Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
standard
posted on 2017-08-01, 00:00 authored by Mark A. Suckow, Paul J. Hall, William R. WolterDisclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvant may also be described as a heterologous acellular collagenous tissue preparation. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.
History
Patent Number
US 9220770 B2Other Application
12/868,908Inventor
Mark A. Suckow William R. Wolter Paul J. HallInventor from Local Institution
Mark A. Suckow William R. WolterAssignee
University of Notre Dame du Lac Cook Biotech, Inc. (West Lafayette, IN)Date Modified
2017-08-01Language
- English
Claims
16Prior Publication Number
2011-03-31Publisher
U.S. Patent and Trademark OfficeCooperative Patent Classification Codes
A61K 39/08 (20130101); A61K 39/39 (20130101); A61K 2039/55511 (20130101); A61K 2039/55588 (20130101)Contributor
Mark A. Suckow|William R. WolterInternational Patent Classification Codes
A61K 39/39 (20060101); A61K 39/00 (20060101); A61K 39/08 (20060101)US Patent Classification Codes
1/1Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC